Graft-versus-host Disease
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-02-17Clinical Trial Update: Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) [Phase 1, Phase 2]
Exploratory safety study of ALD518 in steroid-refractory acute graft-versus-host disease (GVHD) across Phase 1/2, terminated with posted res…
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer [Phase 2]
Phase 2 clinical trial evaluating beclomethasone dipropionate to prevent acute graft-versus-host disease in patients undergoing donor stem c…
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host Disease [Phase 2]
A Phase 2 clinical trial evaluating sitagliptin for grade 3-4 and refractory acute graft-versus-host disease.
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy [NA]
Clinical trial update on changes in physical function measures in stem cell transplant patients at risk for steroid myopathy; study terminat…
-
CLINICAL_TRIALS trial_result · 2020-12-31Clinical Trial Update: MSC for Treatment of cGVHD After Allo-HSCT [Phase 2]
Phase 2 clinical trial update for mesenchymal stem cells aimed at treating chronic graft-versus-host disease after allogeneic hematopoietic …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 trial evaluating sitagliptin for prevention of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantat…
-
CLINICAL_TRIALS trial_result · 2020-12-08Clinical Trial Update: Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease [Phase 2]
Phase 2 trial update comparing twice-weekly intravenous micafungin pharmacokinetics to daily dosing in patients at risk for invasive fungal …
-
CLINICAL_TRIALS trial_result · 2020-11-20Clinical Trial Update: Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT [Phase 2]
Phase 2 trial comparing cyclophosphamide to anti-thymocyte globulin for GVHD prophylaxis after reduced-intensity conditioning allogeneic ste…
-
CLINICAL_TRIALS trial_result · 2020-11-12Clinical Trial Update: Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease [Phase 1, Phase 2]
A Phase 1/2 study evaluating ofatumumab as primary therapy for chronic graft-versus-host disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-01Clinical Trial Update: Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation [Phase 2]
Phase 2 trial update exploring prophylactic IL-2 treatment to prevent or mitigate acute graft-versus-host disease after transplantation.
-
CLINICAL_TRIALS trial_result · 2020-09-25Clinical Trial Update: Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis [Phase 4]
Phase 4 trial update on anti-thymocyte globulins for graft-versus-host disease prophylaxis completed.
-
CLINICAL_TRIALS trial_result · 2020-09-11Clinical Trial Update: Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease [Phase 3]
Phase 3 trial of methoxsalen with extracorporeal photopheresis for pediatric steroid-refractory acute graft-versus-host disease; study termi…
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD [Phase 2]
Phase 2 trial evaluating selective depletion of CD45RA+ T cells from allogeneic peripheral blood stem cell grafts to prevent GVHD; study ter…
-
FDA approval · 2020-08-07FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2020-06-17Clinical Trial Update: Abatacept as GVHD Prophylaxis Phase 2 [Phase 2]
Phase 2 study evaluating abatacept as prophylaxis for graft-versus-host disease showed results for preventing GVHD in transplant patients; r…
-
CLINICAL_TRIALS trial_result · 2020-05-15Clinical Trial Update: GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease [Phase 3]
Final results from GRAVITAS-301, a Phase 3 study evaluating itacitinib plus corticosteroids versus placebo plus corticosteroids for acute gr…
-
FDA approval · 2020-04-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2020-04-17Clinical Trial Update: Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD [Phase 2]
Phase II trial investigating natalizumab plus prednisone for initial therapy of acute GI graft-versus-host disease has completed with result…
-
CLINICAL_TRIALS trial_result · 2020-04-09Clinical Trial Update: Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease [Phase 2]
Phase 2 trial evaluating sirolimus as primary therapy for chronic graft-versus-host disease.
-
CLINICAL_TRIALS trial_result · 2020-04-02Clinical Trial Update: Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus [Phase 2]
Phase 2 trial update on treating newly diagnosed moderate to severe chronic graft-versus-host disease with prednisone and everolimus.
-
CLINICAL_TRIALS trial_result · 2020-03-12Clinical Trial Update: Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD [Phase 2]
Phase 2 trial update on biomarkers in acute graft-versus-host disease and the use of extracorporeal photopheresis added to investigator-chos…
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Maraviroc as GVHD Prophylaxis in Transplant Recipients [Phase 1, Phase 2]
This clinical trial update reports termination of a study evaluating maraviroc for GVHD prophylaxis in transplant recipients, with results p…
-
EMA withdrawal · 2020-02-14EMA Withdrawn: Zalmoxis (allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) — MolMed SpA
The EMA withdrew Zalmoxis, a gene-modified allogeneic T cell product for hematopoietic stem cell transplantation and graft-versus-host disea…
-
CLINICAL_TRIALS trial_result · 2020-01-31Clinical Trial Update: Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease [Phase 1, Phase 2]
Clinical trial updates for tocilizumab in steroid-refractory acute graft-versus-host disease (Phase 1/Phase 2) has terminated with results p…
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD [Phase 3]
A Phase 3 trial comparing BEGEDINA with conventional treatment for steroid-resistant acute graft-versus-host disease was terminated; results…